ARWR Stock Price Today (September 2026) — Arrowhead Pharmaceuticals, Inc. Analysis & Key Metrics 2026-09-03
Arrowhead Pharmaceuticals, Inc. (ARWR) is trading at $86.49, up 1.31% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $110.18 (27.4% upside).
- Volatility remains elevated (28.11% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (1.71% YoY) alongside significant competitive pressures.
ARWR Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Arrowhead Pharmaceuticals, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $11.78B
P/E Ratio
Forward P/E: -17.05
Revenue Growth
Year over Year
Analyst Target
+27.4% upside potential
Key Investor Questions About ARWR
What investors need to know before buying
Based on current market data, ARWR presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 51.81)
- Fundamentals say: Caution warranted (high leverage concerns)
ARWR's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ARWR investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $1.38B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, ARWR stock traded between $22.73 and $95.49—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 28.11% annualized volatility and β=1.67, the stock exhibits high sensitivity to market moves—making ARWR suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Is Arrowhead Pharmaceuticals (ARWR) Undervalued As SHASTA 3 And SHASTA 4 Data Impress?
Arrowhead Pharmaceuticals (ARWR) attracted fresh attention after presenting pivotal Phase 3 SHASTA-3 and SHASTA-4 data for plozasiran at the ESC Congress 2026. The company highlighted triglyceride reductions and fewer acute pancreatitis events in severe hypertriglyceridemia. Arrowhead Pharmaceuticals has seen its share price give back some ground in the past week, with the 1-day share price return down 2.97% and the 7-day share price return down 5%. At the same time, the 90-day share price...
Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials
Arrowhead Pharmaceuticals (NASDAQ:ARWR) presented 12-month results from its Phase 3 SHASTA-3 and SHASTA-4 trials evaluating plozasiran in adults with severe hypertriglyceridemia, reporting substantial reductions in triglycerides and acute pancreatitis events versus placebo. The company said the data
Could Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating?
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) reached a major European milestone on August 17 when it announced the availability of REDEMPLO for adults with Familial Chylomicronemia Syndrome (FCS) in Germany. Following European Commission authorization in June 2026, the drug is now listed in the Lauer-Taxe database for prescribing and reimbursement. Unlike existing options requiring genetic confirmation, REDEMPLO […]
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.
Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ...
Arrowhead Pharmaceuticals Inc (ARWR) reports robust clinical progress and commercial growth, despite a wider net loss in Q3 2026.
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported positive Phase III results for plozasiran in severe hypertriglyceridemia (SHTG), accelerating plans for a supplemental New Drug Application and highlighting continued growth in the launch of its REDEMPLO therapy for familial chylomicronemia syndrome (
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Dual Phase 3 RNAi Cardiometabolic Milestones
Arrowhead Pharmaceuticals recently reported that its siRNA drug plozasiran met all primary and key secondary endpoints in two global Phase 3 trials for severe hypertriglyceridemia, while also completing patient enrollment for the YOSEMITE Phase 3 trial of zodasiran in the ultra-rare condition homozygous familial hypercholesterolemia. Together, these late-stage milestones highlight Arrowhead’s push to expand its RNAi portfolio into high-need cardiometabolic diseases, potentially broadening...
The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High
Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday, leading the stock to skyrocket.
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?
With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.
ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data
Chardan analyst Keay Nakae raised the firm's price target on Arrowhead to $115 from $90 and keeps a Buy rating on the shares.
Explore More Analysis for ARWR
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) is currently trading at $86.49. The RSI (14-day) is at 51.8, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $110.18 implies 27.4% upside from current levels. Volatility is moderate at 28.1% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Arrowhead Pharmaceuticals, Inc. (ARWR): The trailing P/E ratio is -38.96, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -17.05. Price-to-Book is 26.23. Price-to-Sales is 18.25. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 11 analysts covering ARWR, the consensus price target is $110.18. This represents a 27.4% upside from the current price of $86.49. The range spans from a low target of $100.00 to a high target of $126.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Arrowhead Pharmaceuticals, Inc. (ARWR) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Arrowhead Pharmaceuticals, Inc. (ARWR) investors include: 1. Moderate volatility (28.1% annualized)—price swings are notable. 2. Elevated debt levels (D/E ratio of 295.98) which could pressure margins in a rising rate environment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Arrowhead Pharmaceuticals, Inc.'s (ARWR) current debt and financial health profile: Total debt stands at $1.38B. The debt-to-equity ratio is 295.98, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 5.90, indicating strong short-term liquidity. The quick ratio is 5.71. The company holds $1.60B in cash and equivalents. Free cash flow is negative at $-48,628,124, which could limit the company's ability to manage debt obligations.